Kolexia
Slama Borhane Oncologie hémato.
Slama Borhane
Oncologie hémato.
Centre Hospitalier D’Avignon
Avignon, France
144 Activités
167 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Syndromes myélodysplasiques Lymphomes Thrombopénie Purpura thrombopénique idiopathique Leucémies Purpura Purpura thrombopénique Anémie

Collaborateurs

Voir plus
Chebrek Safia
Chebrek Safia
Centre Hospitalier D’Avignon, Avignon, France
Zerazhi Hacene
Zerazhi Hacene
Centre Hospitalier D’Avignon, Avignon, France
Boulat Olivier
Boulat Olivier
Centre Hospitalier D’Avignon, Avignon, France
Cheze Stephane
Cheze Stephane
Hôpital Côte de Nacre, Caen, France

Industries

Voir plus
B3TSI
65 collaboration(s)
Dernière en 2023
A+A
46 collaboration(s)
Dernière en 2023
IQVIA
18 collaboration(s)
Dernière en 2022
Abbvie
11 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Annals of hematology   06 mars 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
IPA-LMC: Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
Essai Clinique (Centre Hospitalier D’Avignon)   29 novembre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
Essai Clinique (The Lymphoma Academic Research Organisation)   25 septembre 2023
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non-Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
KILT: A RANDOMIZED NON-COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Hematology (Amsterdam, Netherlands)   05 mai 2023
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
The 17th International Congress on Myelodysplastic Syndromes   01 mai 2023